ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug candidates targeting
specific pathogens that cause serious infections and diseases,
announced today that its Investor Day to highlight the Company's
irritable bowel syndrome (IBS) program, including its novel, oral
product SYN-010, targeting constipation-predominant IBS (C-IBS),
will be webcast live at 9:00 a.m. EDT
on Tuesday, September 16, 2014.
Synthetic Biologics' IBS Investor Day will feature the Company's
management team and keynote speaker, Dr. Mark Pimentel, Director, GI Motility Program and
Laboratory, Cedars-Sinai Medical Center and Chairman of Synthetic
Biologics' C-IBS Clinical Advisory Board. The presentation will
include an overview of the anticipated clinical and regulatory
pathway for SYN-010 to reduce the impact of methane producing
organisms on C-IBS. Dr. Pimentel will also discuss his
groundbreaking work that led to the discovery of SYN-010, including
the association between the overproduction of methane gas by
microorganisms in the gut and conditions such as C-IBS, as well as
further detail for SYN-010 itself.
Interested parties may log in to the live webcast over the
Internet at SYN IBS Investor Day Webcast. If you are unable to
participate during the live event, the webcast will be available
for replay at the same URL, SYN IBS Investor Day Webcast, for 60
days after the Investor Day.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding Synthetic Biologics'
anticipated clinical and regulatory pathway for SYN-010 The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Synthetic Biologics' forward-looking statements
include, among others, the clinical trials not being conducted when
anticipated and other factors described in Synthetic Biologics'
report on Form 10-K for the year ended December 31, 2013 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.